Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 11/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116556 | 0.84 | SGK1 (0.38) | SGK1SCN9AALPLSCN5A | |
| SCHEMBL2118117 | 0.78 | SLC22A12 (0.36) | SGK1SCN9ALMNATHRBALPL | |
| SCHEMBL2119855 | 0.76 | MEN1 (0.43) | SGK1LMNAMAPT | |
| SCHEMBL2120158 | 0.75 | TP53 (0.40) | SGK1SCN9ATHRBMAPT | |
| SCHEMBL2117885 | 0.75 | ALDH1A1 (0.37) | SGK1SCN9ALMNATHRBMAPT | |
| SCHEMBL2117206 | 0.75 | SYK (0.46) | SGK1THRBMAPT | |
| SCHEMBL2117811 | 0.75 | HPGD (0.50) | LMNAMAPT | |
| SCHEMBL2119820 | 0.74 | MAPT (0.38) | SGK1LMNAMAPT | |
| SCHEMBL2119291 | 0.73 | KMT2A (0.35) | SGK1THRBMAPT | |
| SCHEMBL2119384 | 0.72 | MAPT (0.36) | SGK1SCN9ALMNATHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | SGK1 4188/4885SCN9A 3268/4885LMNA 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.